Iopentol (Imagopaque 300 and 350) compared with iohexol (Omnipaque 300 and 350) in cerebral and aortic arch angiography. A clinical trial assessing adverse events and diagnostic information.
The safety of the non-ionic contrast medium iopentol (Imagopaque, Nycomed Imaging AS, Oslo, Norway) when used in cerebral angiography and aortic arch angiography, was the focus of this investigation. Overall quality of visualization and changes in heart rate and blood pressure were, however, also assessed. In total, 39 patients were injected with iopentol and 41 patients with the comparative contrast medium, iohexol (Omnipaque, Nycomed Imaging AS, Oslo, Norway). Two patients (5%) in each group reported contrast-related adverse events other than a sensation of heat, while three patients in the iopentol group and four in the iohexol group reported procedure-related adverse events. A sensation of heat was reported by 21 patients (54%) in the iopentol group, and by 20 patients (49%) in the iohexol group. There were no clinically relevant changes in heart rate or blood pressure. The diagnostic information obtained was of sufficient or excellent quality for all patients. Statistical analyses did not indicate any significant difference between the two contrast media. Iopentol was well suited for cerebral and aortic arch angiography, comparable to iohexol regarding safety and efficacy.
Ericsson
K
K
Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden.
Bjartveit
K
K
D001013:Aorta, Thoracic / Q000000981:diagnostic imaging; D002533:Cerebral Angiography; D003287:Contrast Media / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007472:Iohexol / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012449:Safety; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007472:Iohexol; C053571:iopentol